Animated course

Direct oral anticoagulants

Seven short animations, five questions after each one, and a sixteen-question assessment with a certificate of completion. Written for doctors in training, pharmacists and specialist nurses. Free, with no registration.

0 of 0 questions answered · clear my answers and start again

Part 1

What a DOAC is, and who it is for

3 min 58 s
  • How the four drugs work, and where
  • The licensed indications
  • What you gain and give up against warfarin
  • The six situations where a DOAC is the wrong answer

Check your understanding

0 of 5 answered

1A 34-year-old woman has new atrial fibrillation. Echocardiography shows moderate rheumatic mitral stenosis. She is otherwise well, with normal renal function. What is the appropriate anticoagulant?

2A 64-year-old man with an oesophageal adenocarcinoma, not yet resected, has a proximal DVT. Which anticoagulant does the animation say is preferred?

3A 71-year-old woman with permanent atrial fibrillation had a surgical bioprosthetic mitral valve replacement six weeks ago. What does the animation say about her anticoagulation?

4In the atrial fibrillation trials, which outcome did the DOACs reduce by around half compared with warfarin?

5Why does a patient who stops taking a DOAC carry a risk that is easier to miss than with warfarin?

How did you find this part?
Anonymous, two clicks. It tells us what is working and what to improve.
Useful
1 = not useful · 5 = very useful
Difficulty
1 = straightforward · 5 = very hard
References for part 1
  • Eikelboom JW et al. Dabigatran versus warfarin in patients with mechanical heart valves (RE-ALIGN). N Engl J Med 2013. link
  • Pengo V et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome (TRAPS). Blood 2018. link
  • Ruff CT et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis. Lancet 2014. link
  • Connolly SJ et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation (INVICTUS). N Engl J Med 2022. link
Part 2

Getting the dose right

6 min 6 s
  • Doses by indication, not by drug
  • VTE loading and the parenteral lead-in
  • Dose-reduction criteria for each of the four
  • Why under-dosing is not the safe option

Check your understanding

0 of 5 answered

1An 81-year-old man with atrial fibrillation weighs 72 kg. His creatinine is 90 µmol/L and his creatinine clearance is 58 mL/min. He has no bleeding history. What apixaban dose should he be prescribed?

2A 76-year-old woman with atrial fibrillation weighs 52 kg. Her creatinine is 98 µmol/L and her creatinine clearance is 35 mL/min. She is frail and has fallen twice this year. What apixaban dose should she be prescribed?

3A patient with an acute pulmonary embolism is to be treated with dabigatran. Which is correct?

4A 70-year-old man with a creatinine clearance of 35 mL/min starts rivaroxaban for an acute pulmonary embolism. What does the animation say is correct?

5Which statement about apixaban 2.5 mg twice daily is correct?

How did you find this part?
Anonymous, two clicks. It tells us what is working and what to improve.
Useful
1 = not useful · 5 = very useful
Difficulty
1 = straightforward · 5 = very hard
References for part 2
  • Steinberg BA et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes (ORBIT-AF II). J Am Coll Cardiol 2016. link
  • Eliquis (apixaban) Summary of Product Characteristics, electronic Medicines Compendium. link
  • Van Gelder IC et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2024. link
  • Camm AJ et al. Non-recommended dosing of DOACs in atrial fibrillation: outcomes in GARFIELD-AF. Eur Heart J Cardiovasc Pharmacother 2020. link
Part 3

Kidneys and body weight

5 min 14 s
  • Cockcroft-Gault against the eGFR your lab reports
  • Renal thresholds drug by drug
  • CKD stage 4, stage 5 and dialysis
  • Obesity, low weight and bariatric surgery
  • When a drug level is worth measuring

Check your understanding

0 of 5 answered

1A 78-year-old woman with atrial fibrillation weighs 40 kg. Her serum creatinine is 95 µmol/L and the laboratory reports an eGFR of 53 mL/min/1.73 m². Her Cockcroft-Gault creatinine clearance is 27 mL/min. Which statement is correct?

2A patient on a DOAC has a creatinine clearance of 40 mL/min and is clinically stable. Using the rule of thumb in the animation, how often should renal function be rechecked?

3A patient with atrial fibrillation is on haemodialysis. Which statement matches the UK Kidney Association guidance described in the animation?

4A 55 kg woman with normal renal function and no interacting drugs starts edoxaban for a pulmonary embolism, after 5 days of low molecular weight heparin. What dose?

5Three weeks after a sleeve gastrectomy, a patient develops a DVT. According to the animation, what is the most appropriate anticoagulant?

How did you find this part?
Anonymous, two clicks. It tells us what is working and what to improve.
Useful
1 = not useful · 5 = very useful
Difficulty
1 = straightforward · 5 = very hard
References for part 3
  • Parker K, Power A, Buka R et al. Anticoagulation for atrial fibrillation in adults with advanced kidney disease: UK Kidney Association clinical practice guideline, 2025. link
  • Martin KA et al. Use of DOACs in patients with obesity: updated communication from the ISTH SSC. J Thromb Haemost 2021. link
  • Pradaxa (dabigatran) Summary of Product Characteristics, electronic Medicines Compendium. link
Part 4

Interactions, switching and the practical traps

5 min 29 s
  • P-glycoprotein and CYP3A4 in two minutes
  • Inducers, inhibitors and the rifampicin problem
  • NSAIDs, antiplatelets and additive bleeding
  • Food, crushing and packaging rules
  • Switching between anticoagulants

Check your understanding

0 of 5 answered

1A 46-year-old man has been taking apixaban 5 mg twice daily for an unprovoked pulmonary embolism diagnosed two months ago. He is now starting standard four-drug antituberculous therapy including rifampicin. What should happen to his anticoagulation?

2A 72-year-old with atrial fibrillation on dabigatran 150 mg twice daily is started on verapamil. What change does the animation describe?

3A patient on edoxaban 60 mg once daily for VTE needs a course of erythromycin. What should happen to the edoxaban?

4A carer wants to put a patient’s dabigatran into a weekly dosette box and open the capsules to mix with food. What advice is correct?

5A patient on warfarin for recurrent VTE is switching to rivaroxaban. At what INR should rivaroxaban be started?

How did you find this part?
Anonymous, two clicks. It tells us what is working and what to improve.
Useful
1 = not useful · 5 = very useful
Difficulty
1 = straightforward · 5 = very hard
References for part 4
  • Steffel J et al. 2021 EHRA Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021. link
  • Xarelto (rivaroxaban) Summary of Product Characteristics, electronic Medicines Compendium. link
  • Lixiana (edoxaban) Summary of Product Characteristics, electronic Medicines Compendium. link
Part 5

Talking to the patient

3 min 56 s
  • Why adherence matters more than with warfarin
  • The missed-dose rule, in writing
  • Which bleeding is expected and which is an emergency
  • Heavy periods, cost and continuity of supply

Check your understanding

0 of 5 answered

1Two patients each take their DOAC at 08:00 and 20:00. Both realise at 16:00 that they missed the morning dose. One takes dabigatran 150 mg twice daily, the other apixaban 5 mg twice daily. According to the product information, what should each do?

2Which symptom should prompt a patient on a DOAC to seek urgent, same-day care?

3On day 5 of rivaroxaban 15 mg twice daily for a DVT, a patient realises at 20:00, when her evening dose is due, that she missed the morning dose. What should she do?

4A 32-year-old woman on rivaroxaban for VTE has very heavy periods and is thinking of stopping her tablets. Which approach is described in the animation?

5Which advice about painkillers bought over the counter is correct for a patient on a DOAC?

How did you find this part?
Anonymous, two clicks. It tells us what is working and what to improve.
Useful
1 = not useful · 5 = very useful
Difficulty
1 = straightforward · 5 = very hard
References for part 5
  • NICE NG196. Atrial fibrillation: diagnosis and management. link
  • Steffel J et al. 2021 EHRA Practical Guide — patient information and adherence. link
  • Bannow BS. Management of heavy menstrual bleeding on anticoagulation. Hematology Am Soc Hematol Educ Program 2020;2020:533–537. link
Part 6

Major bleeding on a DOAC

6 min 38 s
  • The first ten minutes
  • What a normal clotting screen does and does not tell you
  • Idarucizumab, andexanet alfa and PCC
  • When and how to restart

Check your understanding

0 of 5 answered

1A 74-year-old man on dabigatran 150 mg twice daily for atrial fibrillation falls and is brought in with a large intracerebral haemorrhage and a GCS of 11. His last dose was four hours ago and his creatinine clearance is 45 mL/min. After resuscitation, what is the most appropriate specific treatment?

2A patient on a DOAC arrives with major bleeding. Which single piece of history does the animation say tells you most?

3A patient on dabigatran has a normal thrombin time. What does this tell you?

4According to NICE (TA697), for which situation is andexanet alfa recommended?

5A patient with atrial fibrillation has a gastrointestinal bleed on apixaban; the source is secured endoscopically. When does the animation suggest restarting anticoagulation?

How did you find this part?
Anonymous, two clicks. It tells us what is working and what to improve.
Useful
1 = not useful · 5 = very useful
Difficulty
1 = straightforward · 5 = very hard
References for part 6
  • Pollack CV et al. Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med 2017. link
  • Connolly SJ et al. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage (ANNEXA-I). N Engl J Med 2024. link
  • Levy JH, Shaw JR, Castellucci LA, Connors JM, Douketis J, Lindhoff-Last E et al. Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2024;22:2889–2899. link
  • NICE TA697. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban. link
  • NICE TA1029. Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal). link
  • Veltkamp R et al. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF). Lancet 2025. link
  • ENRICH-AF: edoxaban versus no anticoagulation after intracranial haemorrhage in atrial fibrillation. ESC Congress 2026 Hot Line. link
  • Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692–4. link
  • Andexanet alfa pulled from US market (FDA: risks outweigh benefits; ANNEXA-I thrombosis 14.6% vs 6.9%). TCTMD, 2025. link
  • NICE TA697 — list price £11,100 per 4 × 200 mg vials; low-dose course 5 vials, high-dose 9 vials. link
Part 7

Surgery and procedures

7 min 13 s
  • Minimal-risk procedures
  • Thrombotic and procedural bleeding risk
  • The interruption schedule (adapted from CHEST 2022, Figure 2)
  • Why bridging is warfarin thinking
  • Neuraxial anaesthesia (ESAIC/ESRA 2022)
  • Restarting safely, and emergency surgery

Check your understanding

0 of 5 answered

1A 72-year-old woman with atrial fibrillation takes rivaroxaban 20 mg once daily. Her creatinine clearance is 70 mL/min. She is listed for an elective total knee replacement under general anaesthesia on a Thursday morning. What is the correct plan?

2A patient on apixaban needs a single dental extraction. What does the animation advise?

3A patient on apixaban with normal renal function is listed for a short, uncomplicated laparoscopic inguinal hernia repair under general anaesthesia, expected to take under 45 minutes, on a Thursday. When is the last dose?

4A patient on dabigatran with a creatinine clearance of 40 mL/min is listed for major abdominal surgery. According to the CHEST schedule, what changes compared with the standard high-risk schedule?

5A patient had an epidural catheter for postoperative analgesia. When can the DOAC be restarted?

How did you find this part?
Anonymous, two clicks. It tells us what is working and what to improve.
Useful
1 = not useful · 5 = very useful
Difficulty
1 = straightforward · 5 = very hard
References for part 7
  • Douketis JD et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest 2022;162:e207–e243. link
  • Veitch AM et al. Endoscopy in patients on antiplatelet or anticoagulant therapy: BSG and ESGE guideline update. Gut 2021 / Endoscopy 2021;53. link
  • Kopp SL et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: ASRA guidelines, 5th edition. Reg Anesth Pain Med 2025. link
  • Kietaibl S et al. Regional anaesthesia in patients on antithrombotic drugs: joint ESAIC/ESRA guidelines. Eur J Anaesthesiol 2022;39:100–132. link
  • SDCEP. Management of dental patients taking anticoagulants or antiplatelet drugs, 2nd edition. link
  • Douketis JD et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant (PAUSE). JAMA Intern Med 2019. link
  • Douketis JD, Spyropoulos AC. Perioperative management of patients taking direct oral anticoagulants: a review. JAMA 2024. link

End-of-course assessment

Answer the five questions after each of the seven parts to unlock the assessment.

Sixteen questions across the whole series. The pass mark is 13 out of 16. Questions and options are shuffled on each attempt, and you may retake it as often as you like.

Your feedback on the whole course

How was the course overall?
Anonymous. Tell us what worked, what did not, and what you would like next.
Useful
1 = not useful · 5 = very useful
Length
1 = too short · 3 = about right · 5 = too long
Educational use only. For professional education only. This animation is a simplified summary and is not medical advice or a prescribing protocol. Doses and thresholds are those in the UK and EU product information at the date shown; always check the current summary of product characteristics and your local policy before prescribing. Information accurate on 17 October 2026.